Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Dr Lemuel A Moye III, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT00684060
First received: May 22, 2008
Last updated: January 18, 2013
Last verified: January 2013

May 22, 2008
January 18, 2013
July 2008
August 2011   (final data collection date for primary outcome measure)
  • Global Left Ventricular Function [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Left ventricular ejection fraction (global) as assessed via cardiac MRI. Values reported represent the change in Global EF from baseline to six months.
  • Regional Left Ventricular Function (Infarct Zone Wall Motion) [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    One of two calculated values of regional left ventricular function as assessed via cardiac MRI. The infarct zone is defined as the cMRI segments with the largest 2 signal intensity enhancement measures with gadolinium (using a 17-segment model).Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.
  • Regional Left Ventricular Function (Border Zone Wall Motion) [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Two of two calculated values of regional left ventricular function assessed via cardiac MRI. The border zone is defined as those regions adjacent to the infarct zone in which the cMRI signal intensity enhancement were in the 10%-75% range. Values reported represent the change in wall motion over time in the border zone of the infarct from baseline to six months.
Left ventricular ejection fraction (global and regional) [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00684060 on ClinicalTrials.gov Archive Site
  • Combined Endpoint [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: Yes ]
    Combined endpoint: first of death, reinfarction, repeat revascularization, and hospitalization for heart failure. This is measured as the proportion of patients who have at least one of these outcomes by six months.
  • Left Ventricular Mass [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Left ventricular mass (LV mass. Values reported represent the change in LV mass from baseline to six months.)
  • End Diastolic Volume Index [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Left ventricular end diastolic volume index. Values reported represent the change in LV end diastolic index from baseline to six months.
  • End Systolic Volume Index [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Left ventricular end systolic volume index. Values reported represent the change in LV end systolic volume index from baseline to six months.
  • Infarct Volume [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Infarct volume(mL). Values reported represent the change in infarct volume from baseline to six months.
  • Combined endpoint: first of death, reinfarction, repeat revascularization, and hospitalization for heart failure [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: Yes ]
  • Left ventricular mass [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: Yes ]
  • End diastolic volume [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: Yes ]
  • End systolic volume [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: Yes ]
  • Infarct size [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction

More than 1 million Americans suffer heart attacks each year. Although current treatments are able to stabilize the condition of the heart, none is able to restore heart function as it was prior to the heart attack. Adult stem cells, which are immature cells that can become many different types of cells, may offer a potential means of reversing or preventing permanent damage caused by a heart attack. Recent studies have shown promise in using adult stem cells from bone marrow to reverse damage to the heart muscle caused by a heart attack, but more research is needed to assess the safety and effectiveness of stem cell use and to discover the best time to administer treatment. This study will evaluate the safety and effectiveness of using adult stem cell infusions 2 to 3 weeks after a heart attack for improving heart function in people who have had a recent heart attack and a common procedure called a percutaneous coronary intervention (PCI).

Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary arteries. If the clot becomes large enough, blood flow to the heart can be blocked almost completely and the heart muscle in that area can suffer permanent injury or death. Although a PCI can be used to open up the blocked artery and restore blood flow to the heart muscle, there may be a significant amount of heart tissue that has been irreversibly damaged. Recent studies have shown that adult stem cells from bone marrow may be able to improve heart function after a heart attack. These specialized cells may have the ability to promote blood vessel growth, prevent cell death, and transform themselves into a number of tissues, including muscle. After an acute heart attack, a remodeling process is initiated in the heart in an attempt to compensate for damaged areas. Consequently, the condition of the heart muscle several weeks after a heart attack may differ considerably from the heart's condition during the acute setting. For some patients, delaying the delivery of the stem cells until 2 to 3 weeks after a heart attack may be better than initiating treatment during the acute phase. This study will evaluate the safety and effectiveness of placing adult stem cells into injured heart muscle 2 to 3 weeks after a heart attack for improving heart function in people who have had a recent heart attack and a PCI.

Participation in this study will last 24 months. All participants will first undergo baseline assessments that will include a medical history, a physical exam, an electrocardiogram (ECG), blood draws, an echocardiogram, and a magnetic resonance imaging (MRI) test. Participants will then be assigned randomly to receive stem cells or placebo between 2 and 3 weeks after their heart attack. The morning of the stem cell or placebo infusion, participants will undergo a blood draw and a bone marrow aspiration procedure of the hip bone to collect the stem cells. Later the same day, either stem cells or placebo will be infused through a catheter and into the damaged area of the heart.

For the first 24 hours after the infusion, participants will be asked to wear a small ECG machine called a Holter monitor. Participants will also be asked to record their temperature twice a day for a month after the infusion. Participants will return for follow-up visits at Months 1, 3, 6, 12, and 24 and will repeat many of the baseline assessments.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Left Ventricular Dysfunction
  • Biological: Adult stem cells
    One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
    Other Names:
    • Adult autologous stem cells
    • Bone marrow mononucleated cells
  • Biological: Placebo
    One time infusion of 30 ml of HSA (5%)
    Other Names:
    • Human serum albumin
    • HSA
  • Experimental: 1
    Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
    Intervention: Biological: Adult stem cells
  • Placebo Comparator: 2
    Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.
    Intervention: Biological: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
87
February 2012
August 2011   (final data collection date for primary outcome measure)

Inclusion criteria

  1. Patients at least 21 years of age.
  2. Patients with first acute MI and subsequent successful primary percutaneous coronary intervention (PCI) in an artery at least 2.5 mm in diameter occurring two to three weeks before recruitment.
  3. No contraindications to undergoing cell therapy procedure within two to three weeks following AMI and PCI.
  4. Hemodynamic stability as defined as no requirement for IABP, inotropic or blood pressure supporting medications.
  5. Ejection fraction following reperfusion with PCI <=45% as assessed by echocardiography.
  6. Consent to protocol and agree to comply with all follow-up visits and studies.
  7. Women of child bearing potential willing to use an active form of birth control.

Exclusion criteria

Patients will be excluded from the study if they meet any of the following conditions:

  1. History of sustained ventricular arrhythmias not related to their AMI (evidenced by previous holter monitoring and/or medication history for sustained ventricular arrhythmias in patient's medical chart).
  2. Require CABG or PCI due to the presence of residual coronary stenosis >70% luminal obstruction in the non-infarct related vessel (Additional PCI of non-culprit vessels may be performed prior to enrollment).
  3. History of any malignancy within the past five years excluding non-melanoma skin cancer or cervical cancer in-situ.
  4. History of chronic anemia (hemoglobin (Hb) <9.0 mg/dl).
  5. History of thrombocytosis (platelets >500k).
  6. History of thrombocytopenia in the absence of recent evidence that platelet counts are normal
  7. Known history of elevated INR (PT) or PTT.
  8. Life expectancy less than one year.
  9. History of untreated alcohol or drug abuse.
  10. Currently enrolled in another Investigational drug or device trial
  11. Previous CABG.
  12. Previous MI resulting in LV dysfunction (LVEF <55%)
  13. History of stroke or transient ischemic attack (TIA) within the past six months.
  14. History of severe valvular heart disease (aortic valve area <1.0 cm2 or >3+ mitral regurgitation).
  15. Pregnancy or breast feeding
  16. Subjects with a known history of HIV, or has active hepatitis B, active hepatitis C, or active tuberculosis (TB)
  17. Patients with active inflammatory or autoimmune disease on chronic immunosuppressive therapy.
  18. Contraindications to cMRI.
  19. Previous radiation to the pelvis with white blood cell count (WBC) and platelet counts below hospital specific normal values.
  20. Women child bearing potential not willing to practice an active form of birth control.
  21. Chronic liver disease that might interfere with survival or treatment with cell therapy.
  22. Chronic renal insufficiency as defined by a creatinine ≥2.0 mg/dL or requires chronic dialysis.
Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00684060
578, 1U01HL087318, 1 U01-HL-087318-01 (Project 2)
Yes
Dr Lemuel A Moye III, The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
National Heart, Lung, and Blood Institute (NHLBI)
Study Chair: Robert Simari, MD Cardiovascular Cell Therapy Research Network
The University of Texas Health Science Center, Houston
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP